Investor Presentaiton

Novo Nordisk Annual Report 2023 Independence and meeting attendance overview Introducing Novo Nordisk Strategic Aspirations Risks Management Consolidated statements Additional information Meeting attendance in 20233 Board of Name Helge Lund Henrik Poulsen Independence Directors Chair Committee Audit Nomination Committee 10 Committee Remuneration R&D Committee Committee Independent 9/9 7/7 3/3 Not independent 56.7.9 9/9 7/7 5/5 5/6 Elisabeth Dahl Christensen Not independent³ 9/9 6/6 Laurence Debroux Independent 6.7,9 9/9 5/5 6/6 Andreas Fibig Sylvie Grégoire Independent 9/9 4/4 Independent 9/9 5/5 3/3 4/4 Liselotte Hyveled Not independent 8/9 4/4 Mette Bøjer Jensen Not independent6,8 9/9 5/5 Kasim Kutay Not independent 8/9 3/3 4/4 Christina Law Independent 9/9 5/5 Martin Mackay Independent 9/9 Thomas Rantzau Not independent 9/9 6/6 4/4 3/3 Board members who stepped down at the Annual General Meeting in March 2023 Jeppe Christiansen Not independent 2/2 1/2 3. Number of meetings attended by each Board member out of the total number of meetings within the member's term. 4. In accordance with recommendation 3.2.1 of the Danish Corporate Governance Recommendations as designated by Nasdaq Copenhagen. 5. Member of the board of directors or executive management of Novo Holdings A/S. 6. Pursuant to the US Securities Exchange Act, Ms Debroux, Ms Grégoire and Ms Law qualify as independent Audit Committee members, while Ms Bøjer Jensen and Mr Poulsen rely on an exemption from the independence requirements. 7. Ms Debroux and Mr Poulsen possess the qualifications within accounting and auditing required under part 8 of the Danish Act on Approved Auditors and Audit Firms. 8. Elected by employees of Novo Nordisk. 9. Designated as financial experts as defined by the US Securities and Exchange Commission (SEC). 10. Collectively, the members have relevant industry expertise. Lars Fruergaard Jørgensen and Helge Lund (left) during the Annual General Meeting in March 2023. بی 47 46

View entire presentation